The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS).
 
Sant P. Chawla
Honoraria - Amgen; Cybox; Johnson & Johnson; Morphotek; PharmaMar; Threshold Pharmaceuticals; TRACON Pharma
Consulting or Advisory Role - Amgen; Cybox; Johnson & Johnson; Morphotek; PharmaMar; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Amgen; Cybox; Johnson & Johnson; Morphotek; PharmaMar; Threshold Pharmaceuticals; TRACON Pharma
Travel, Accommodations, Expenses - Amgen; Cybox; Johnson & Johnson; Morphotek; PharmaMar; Threshold Pharmaceuticals; TRACON Pharma
 
Patrick Schöffski
Honoraria - Daiichi Sankyo; Medpace
Consulting or Advisory Role - Adaptimmune (Inst); amcure (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); cristal therapeutics (Inst); Eisai (Inst); Lilly (Inst); Novartis (Inst); Philogen (Inst); Piqur (Inst); Swedish Orphan Biovitrum (Inst)
Speakers' Bureau - Bayer; Eisai; GlaxoSmithKline; Lilly; Novartis; Swedish Orphan Biovitrum
Research Funding - Bayer (Inst); Blueprint Medicines (Inst); CoBioRes NV (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Giovanni Grignani
Honoraria - Bayer; PharmaMar
Consulting or Advisory Role - Bayer; Eisai; Pharmamar
Travel, Accommodations, Expenses - PharmaMar
 
Jean-Yves Blay
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pharmamar; Roche
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Merck; Novartis; PharmaMar; Roche
Research Funding - GlaxoSmithKline (Inst); Novartis (Inst); Pharmamar (Inst)
 
Robert G. Maki
Stock and Other Ownership Interests - Gilead Sciences
Honoraria - Janssen
Consulting or Advisory Role - Arcus Ventures; Bayer; Eisai; Gem Pharmaceuticals; Lilly/ImClone; SARC: Sarcoma Alliance for Research though Collaboration; TRACON Pharma
Research Funding - Epizyme (Inst); Immune Design (Inst); Lilly (Inst); Novartis (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Uptodate: I write and edit chapters for their online text book.
Travel, Accommodations, Expenses - Bayer/Onyx; Janssen Oncology; TRACON Pharma
 
David R. D'Adamo
Employment - Eisai
Travel, Accommodations, Expenses - Eisai
 
Matthew Guo
Employment - Eisai
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Eisai
 
George D. Demetri
Leadership - Blueprint Medicines
Stock and Other Ownership Interests - Bessor Pharma; Blueprint Medicines; Caris Life Sciences; Champions Oncology; G1 Therapeutics; Kolltan Pharmaceuticals
Consulting or Advisory Role - ARIAD; Bayer; Bessor Pharma; Blueprint Medicines; Caris Life Sciences; Champions Oncology; Daiichi Sankyo; EMD Serono; G1 Therapeutics; Genocea Biosciences; Janssen Oncology; Kolltan Pharmaceuticals; Kyocera; Lilly; Nektar; Novartis; Pfizer; PharmaMar; Polaris; Sanofi; WIRB-Copernicus Group; ZIOPHARM Oncology
Research Funding - Bayer (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Novartis (Inst)